Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Calibr, a division of Scripps Research
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Men ≥ 18 years of age at time of informed consent
For Part 1 and Part 2: men with metastatic castration resistant prostate cancer (mCRPC) with histologically or cytologically confirmed adenocarcinoma of the prostate as defined by one or more of the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria
Must have prostate-specific antigen (PSA) and/or radiographic progression on AT LEAST One novel androgen receptor (AR)-targeted therapy (abiraterone acetate, enzalutamide).
Eastern Cooperative Oncology Group performance status of 0-1
Adequate liver function
Adequate hematopoietic function
Testosterone level ≤ 50 ng/mL (or 1.73 nmol/L)
Patient has a life expectancy of greater than 12 weeks
You may not be if
Patients whose tumors solely exhibit neuroendocrine differentiation or small cell features by histopathology
Patients with new or progressive brain metastasis or Leptomeningeal Disease (LMD)
Patients with a history of clinically significant cardiovascular disease such as symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, history of stroke or myocardial infarction within 6 months of enrollment
Patients with peripheral neuropathy CTCAE Grade \>/= 2
Patients with a known history of hypersensitivity, allergy or intolerance to CCW702 or its excipients
Patients with untreated or imminent spinal cord compression
Clareo Health | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
